You are not logged in so some information on this page has been withheld. To see more, please log in.

CagriSema

since 2025 › Jan › 23 (Thu) @ 21:48 UTC

auto-detected in 21 stories

68 days ago

Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

found 2025 › Mar › 28 (Fri) @ 16:37 UTC

a story from CNBC ⚠ › World News

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'

found 2025 › Mar › 28 (Fri) @ 16:37 UTC

a story from CNBC ⚠ › Top News

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

71 days ago

Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure

found 2025 › Mar › 25 (Tue) @ 07:00 UTC

a story from CNBC ⚠ › World News

Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

86 days ago

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

found 2025 › Mar › 10 (Mon) @ 12:54 UTC

a story from CNBC ⚠ › Europe News

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

found 2025 › Mar › 10 (Mon) @ 12:54 UTC

a story from CNBC ⚠ › World News

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

found 2025 › Mar › 10 (Mon) @ 12:54 UTC

a story from CNBC ⚠ › Top News

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

3 months ago

Trump fears drive gold to record high, as yuan hit by US-China trade war – business live

found 2025 › Feb › 05 (Wed) @ 08:38 UTC

a story from The Guardian ⚠ › International

Rolling coverage of the latest economic and financial news

Novo Nordisk has reported better-than-expected revenues, with sales of its Wegovy obesity drug surging by 86% last year, but expects growth t…

5 months ago

Novo Nordisk shares tumble as data on weight-loss drug trial disappoints

found 2024 › Dec › 20 (Fri) @ 18:41 UTC

a story from Financial Times ✅ › Financial Times

Obesity treatment CagriSema misses goal of 25% reduction in body weight

page 1 of 1